U.S. FDA Approves Blenrep for the Treatment of Relapsed/Refractory Multiple Myeloma
October 24, 2025
October 24, 2025
NORTH HOLLYWOOD, California, Oct. 24 -- The International Myeloma Foundation issued the following news on Oct. 23, 2025:
* * *
U.S. FDA Approves Blenrep for the Treatment of Relapsed/Refractory Multiple Myeloma
On Thursday, October 23, 2025, the U.S. Food and Drug Administration (FDA) announced its approval of Blenrep(R) (belantamab mafodotin-blmf)-- "a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate -- with borte . . .
* * *
U.S. FDA Approves Blenrep for the Treatment of Relapsed/Refractory Multiple Myeloma
On Thursday, October 23, 2025, the U.S. Food and Drug Administration (FDA) announced its approval of Blenrep(R) (belantamab mafodotin-blmf)-- "a B-cell maturation antigen (BCMA)-directed antibody and microtubule inhibitor conjugate -- with borte . . .